A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies

dc.contributor.authorChiorean, E. Gabriela
dc.contributor.authorPorter, Jennifer M.
dc.contributor.authorFoster, Anne E.
dc.contributor.authorOmari, Amal S.H. Al
dc.contributor.authorYoder, Christy A.
dc.contributor.authorFife, Karen L.
dc.contributor.authorStrother, R. Matthew
dc.contributor.authorMurry, Daryl J.
dc.contributor.authorYu, Menggang
dc.contributor.authorJones, David R.
dc.contributor.authorSweeney, Christopher J.
dc.contributor.departmentBiostatistics, School of Public Healthen_US
dc.date.accessioned2020-12-16T15:19:48Z
dc.date.available2020-12-16T15:19:48Z
dc.date.issued2008-02
dc.description.abstractPurpose: This study aimed to define the maximum tolerated dose of weekly docetaxel combined with daily erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor. Experimental Design: Patients with any solid tumor received 150 mg erlotinib with escalating doses of docetaxel (20, 25, 30, and 35 mg/m2) on days 1, 8, and 15 every 28 days. The pharmacokinetics of docetaxel and erlotinib was determined on cycle 2, day 1. Erlotinib was given for a maximum of 12 cycles and docetaxel was given for up to 6 cycles. Results: Twenty-five patients (17 males and 8 females) were enrolled with a median age of 56 years (range, 34-76); Eastern Cooperative Oncology Group performance status of 0/1 was 20/5. One patient had a dose-limiting toxicity in cycle 1 at the 25 mg/m2 level (grade 3 enterocolitis). At 35 mg/m2 docetaxel dose level, 6 of 10 patients required dose reductions to 30 mg/m2 beyond cycle 1 due to neutropenia (3 patients) and mucositis, increased bilirubin, and diarrhea (1 patient each). The clearance of docetaxel and erlotinib of 61.7 and 8.16 L/h, respectively, did not seem to differ from historical controls. Responses were seen in non–small cell lung cancer, prostate cancer, and hepatobiliary cancers, including a complete response lasting 36+ months in a patient with hepatocellular carcinoma. Conclusion: Although no maximum tolerated dose was reached in cycle 1 with 35 mg/m2 docetaxel, repetitive dosing proved intolerable in a substantial number of patients; thus, the recommended phase II dose of weekly docetaxel is 30 mg/m2 when combined with 150 mg of daily erlotinib.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationChiorean, E. G., Porter, J. M., Foster, A. E., Al Omari, A. S., Yoder, C. A., Fife, K. L., ... & Sweeney, C. J. (2008). A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clinical cancer research, 14(4), 1131-1137.en_US
dc.identifier.urihttps://hdl.handle.net/1805/24627
dc.language.isoen_USen_US
dc.publisherAmerican Association of Cancer Researchen_US
dc.relation.isversionof10.1158/1078-0432.CCR-07-0437en_US
dc.relation.journalClinical Cancer Researchen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourcePublisheren_US
dc.subjectPharmacokinetic Trialen_US
dc.subjectErlotiniben_US
dc.subjectWeekly Docetaxelen_US
dc.titleA Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignanciesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1131.full.pdf
Size:
229.99 KB
Format:
Adobe Portable Document Format
Description:
Main Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: